1) IDC-NOS
非特殊型浸润性导管癌
1.
MethodsWe analyzed Fez1/Lzts1 protein expression in IMPC and invasive ductal carcinoma,no specific type(IDC-NOS) by IHC.
【方法】采用免疫组织化学LSAB法检测100例IMPC中Fez1/Lzts1蛋白的表达,选取100例非特殊型浸润性导管癌(IDC-NOS)作为对照,比较Fez1/Lzts1蛋白在不同病理学类型中表达的差异,分析IMPC中Fez1/Lzts1蛋白的表达与淋巴结转移等相关病理学特征的关系;运用重亚硫酸盐处理基因组DNA-PCR扩增。
2) Non-special type invasive carcinoma of breast
乳腺浸润性非特殊型癌
3) nonspecific invasive breast carcinoma
浸润性非特殊癌
1.
Background and Objective: To investigate the factors related with axillary Lymph node metastases from nonspecific invasive breast carcinoma and to provide scientific basis for deciding conditions of breast cancer patients and giving auxiliary treatments after radical mastectomy.
目的:探讨乳腺浸润性非特殊癌腋淋巴结转移的相关因素。
4) infiltrating ductal carcinoma
浸润性导管癌
1.
Differential proteomic analysis in stage Ⅱ breast infiltrating ductal carcinoma tissue with negative estrogen receptor
ER~- Ⅱ期乳腺浸润性导管癌的差异表达蛋白质分析
2.
Objective:The aim of this study was to investigate the X-ray features of infiltrating ductal carcinoma and to analysis its pathological basis and to rise the level of the preoperative diagnostic accuracy.
目的:研究浸润性导管癌的X线表现,分析其病理学基础,以提高乳腺癌手术前的诊断水平。
3.
Purpose To detect the expression of matrix metalloproteinase-26(MMP-26) in human benign and malignant breast tissues,to evaluate the relationship of MMP-26 expression in infiltrating ductal carcinoma(IDC)with clinicopathological parameters and its potential value in tumor progression and to explore the correlation of MMP-26 with estrogen receptor(ER).
方法应用免疫组化SP法,检测MMP-26蛋白在正常乳腺组织、乳腺增生症、原位癌和乳腺浸润性导管癌(IDC)中的表达,以及ER在IDC中的表达并进行评分,结果用INSTAT统计软件分析。
5) Invasive ductal carcinoma
浸润性导管癌
1.
Expression of Ezrin and Galectin-3 and their clinicopathological significance in breast invasive ductal carcinoma;
乳腺浸润性导管癌中Ezrin、Galectin-3的表达及临床病理意义
2.
Reproducibility in evaluating immunohistochemical results of HER2 expression in breast invasive ductal carcinoma;
乳腺浸润性导管癌HER2免疫组化检测结果判定的重复性研究
3.
Expression and clinicopathologic significance of Ki-67 in breast invasive ductal carcinoma;
乳腺浸润性导管癌Ki-67表达及其临床病理学意义
6) IDC
浸润性导管癌
1.
Objective To study the relationship between the expression of p57KIP2 and clinicopathological characteristics in invasive duct carcinoma(IDC).
目的研究p57KIP2在乳腺浸润性导管癌(invasive duct carcinoma,IDC)中的表达及与临床病理特征的关系。
2.
Objective To study the expression cyclinD1,and p57KIP2in invasive duct carcinoma (IDC) and their clinical significances.
目的研究cyclinD1、p57KIP2在乳腺浸润性导管癌(IDC)中的表达及意义。
3.
[Background and Objective] Breast cancer is one of the most common malignant tumors in women with 75% of which exhibiting invasive ductal carcinoma (IDC) when diagnosed.
乳腺癌的75%表现为浸润性导管癌,目前按病理学进程大致将其发生划分为正常乳腺上皮→增生→不典型增生→原位癌→浸润性癌→转移性癌等几个阶段,但其过程中确切分子机制至今仍不详。
补充资料：非特
〈书〉不但。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条